Comparative Pharmacology
Head-to-head clinical analysis: CELONTIN versus OXCARBAZEPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELONTIN versus OXCARBAZEPINE.
CELONTIN vs OXCARBAZEPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases levels of gamma-aminobutyric acid (GABA) in the central nervous system, possibly by inhibiting GABA transaminase or enhancing GABA release; also reduces calcium influx into neurons, stabilizing neuronal membranes.
Stabilization of neuronal membranes by blockade of voltage-sensitive sodium channels, leading to inhibition of repetitive firing and reduction of neurotransmitter release.
300 mg orally three times daily, increased by 300 mg every 3-4 days as tolerated; usual maintenance dose 900-2400 mg/day in divided doses.
Initial 300 mg orally twice daily; increase by 300 mg/day every third day to target dose of 600-1200 mg/day in two divided doses. Maximum 2400 mg/day.
None Documented
None Documented
Clinical Note
moderateOxcarbazepine + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Cobicistat
"The serum concentration of Cobicistat can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Saxagliptin
Terminal elimination half-life: 40-60 hours in adults, 30-45 hours in children; prolonged liver disease or renal impairment may increase half-life.
Oxcarbazepine: 2 hours (parent drug); MHD (active metabolite): 9 hours. Steady-state achieved in 2-3 days. Context: shorter t1/2 than carbamazepine; MHD t1/2 extended in renal impairment (up to 19 hours).
Renal: approximately 40-60% as unchanged drug; hepatic metabolism accounts for the remainder, with metabolites excreted renally.
Renal: 70% (mainly as glucuronide metabolites, unchanged drug <1%). Fecal: negligible.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Saxagliptin can be decreased when it is combined with Oxcarbazepine."